ACM
ANIK icon

Ativo Capital Management’s Anika Therapeutics ANIK Stock Holding History

Ativo Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-19,546
Closed -$1.05M – 219
2017
Q4 		$1.05M Buy
19,546
+1
+0% +$55 0.28% 174
2017
Q3 		$1.13M Hold
19,545
– – 0.3% 152
2017
Q2 		$964K Buy
19,545
+7,543
+63% +$347K 0.26% 172
2017
Q1 		$521K Buy
+12,002
New +$573K 0.13% 217

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return

Ativo Capital Management's ANIK Position: Q1 2018 in Review

Ativo Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2018, closing a stake of 19,546 shares — an estimated $1.05M sold.

Ativo Capital Management first reported a position in ANIK in Q1 2017 and held it in 4 quarters. The position peaked at $1.13M in Q3 2017. 170 funds tracked by Wall St. Rank hold ANIK as of Q1 2018.

  • Ativo Capital Management reported no remaining Anika Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ativo Capital Management sold 19,546 Anika Therapeutics shares in Q1 2018, an estimated $1.05M.
  • Ativo Capital Management first reported a position in Anika Therapeutics in Q1 2017 and held it in 4 quarters.
  • Ativo Capital Management's Anika Therapeutics position peaked at $1.13M in Q3 2017.
  • 170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2018.

Based on Ativo Capital Management's 13F filing for Q1 2018, filed 15 May 2018.